The Chemours Company Reports First Quarter 2025 Results

The Chemours Company (“Chemours” or “the Company”) (NYSE: CC), a global chemistry company with leading market positions in Thermal & Specialized Solutions (“TSS”), Titanium Technologies (“TT”), and Advanced Performance Materials (“APM”), today announced its financial results for the first quarter 2025.

Key First Quarter 2025 Results & Highlights¹

• Net Sales of $1.4 billion, in line with the corresponding prior-year quarter, with TSS achieving year-over-year growth of 40% in Opteon™ Refrigerants
• Net Loss attributable to Chemours of $4 million, or $0.03 per diluted share, compared with Net Income attributable to Chemours of $54 million, or $0.36 per diluted share, in the corresponding prior-year quarter
• Adjusted Net Income² of $19 million, or $0.13 per diluted share, compared with $47 million, or $0.31 per diluted share, in the corresponding prior-year quarter
• Adjusted EBITDA ^{1 ,3} of $166 million compared to $191 million in the corresponding prior-year quarter
• Signed a liquid cooling asset manufacturing agreement with Navin Fluorine International, Ltd. to produce two-phase immersion cooling fluid
• Returned cash to shareholders through dividends of $37 million in the quarter and declared a reduced second quarter dividend to enable balance sheet flexibility going forward

“We made important progress against the key pillars of our Pathway to Thrive strategy with notable advancements in our Enabling Growth pillar, driving year-over-year Opteon^™ growth, supported by the completion of our Corpus Christi, Texas Opteon^™ capacity expansion, and initial manufacturing commitment to develop two-phase immersion cooling fluid. More broadly, we experienced continued, strong demand for Opteon^™ Refrigerants, with 40% year-over-year Net Sales growth,” said Denise Dignam, Chemours President and CEO. “While we experienced some headwinds across all three businesses, macroeconomic and business-related, we remain steadfast in executing our strategy, focusing on driving long-term shareholder value.”

Total Chemours

First quarter 2025 Net Sales of $1.4 billion were in line with the prior-year quarter. A 5% increase in volume was partially offset by a 4% decrease in price, with currency a slight 1% headwind.

First quarter 2025 Net Loss attributable to Chemours was $4 million, or $0.03 per diluted share, compared to Net Income attributable to Chemours of $54 million, or $0.36 per diluted share in the prior-year quarter primarily driven by business performance and restructuring charges associated with the announced shut down of APM’s Surface Protection Solutions (“SPS”) Capstone™ business. Adjusted EBITDA for the first quarter of 2025 was $166 million, compared to $191 million in the prior-year quarter. The decrease in Adjusted EBITDA was primarily driven by lower pricing across business segments, primarily due to Freon™ weakness in TSS and regional pricing dynamics in TT, along with unfavorable currency movements and decreased volumes in APM. This was partially offset by increased Opteon™ Refrigerant blends volumes in TSS and lower costs in APM.

Thermal & Specialized Solutions

TSS segment first quarter 2025 Net Sales were $466 million, a 3% increase compared to the first quarter 2024. Net Sales growth was primarily driven by a volume increase of 10%, partially offset by a price decrease of 6%, with currency as a slight 1% headwind. Volume growth was driven by stronger demand for Opteon™ Refrigerant blends in connection with the stationary air conditioning OEM transition under the U.S. AIM Act, paired with increased demand for FP&O products in the quarter due to timing, partially offset by lower volumes for Freon™ Refrigerant products in connection with the U.S. AIM Act regulatory transition. The decrease in pricing was primarily attributed to lower Freon™ Refrigerant pricing due to elevated hydrofluorocarbon (“HFC”) inventory market levels.

TSS segment first quarter 2025 Adjusted EBITDA decreased 6% to $141 million compared to the prior-year quarter, while Adjusted EBITDA Margin also decreased 3 percentage points to 30%. This decrease was driven primarily by the previously mentioned decrease in price, partially offset by the increased demand for Opteon™ Refrigerant blends products.

On a sequential basis, Net Sales increased by 19%, driven by a volume increase of 19% and a price increase of 1%, with currency a slight 1% headwind. Overall volume and price increases were primarily related to typical seasonal trends across refrigerant portfolios amid the stationary transition under the U.S. AIM Act.

Titanium Technologies

TT segment first quarter 2025 Net Sales were $597 million, a 1% increase compared to the first quarter 2024. This increase was primarily driven by a 6% increase in volume concentrated in western markets⁴ where fair trade regulations have been established, partially offset by a 4% decrease in price across all markets, with currency a slight 1% headwind.

TT segment first quarter 2025 Adjusted EBITDA decreased 28% to $50 million compared to the prior-year quarter, while Adjusted EBITDA Margin decreased by 4 percentage points to 8%. The decrease was primarily driven by the referenced decrease in price. The TT segment also encountered operational headwinds primarily related to cold weather downtime at its U.S sites in January 2025, which were offset by continued cost savings.

On a sequential basis, TT segment first quarter 2025 Net Sales decreased 6%, driven by a 3% decrease in volume and a 3% decrease in price, while currency impact remained flat. While experiencing stronger volumes in western markets where fair trade regulations have been established, these increases were more than offset by weaker volumes in the rest of the world.

Advanced Performance Materials

APM segment first quarter 2025 Net Sales were $294 million, a 3% decrease compared to the first quarter 2024. The change in Net Sales was primarily driven by a 2% currency headwind from the EUR and 1% decrease in volume, while pricing remained flat. The volume decrease was primarily driven by weakness in cyclical end markets and products serving hydrogen markets.

APM segment first quarter 2025 Adjusted EBITDA increased 7% to $32 million compared to the prior-year quarter, while Adjusted EBITDA Margin increased 1 percentage point to 11%. The increase was primarily due to lower costs partially offset by the previously mentioned unfavorable currency movements and lower volumes.

On a sequential basis, APM segment first quarter 2025 Net Sales decreased by 9%, driven by a 9% volume decrease, partially offset by a 1% increase in price, with currency a slight 1% headwind.

In January 2025, under the Portfolio Management pillar of Pathway to Thrive, as a part of a broader strategic review of our APM European asset footprint, APM management approved a restructuring program to exit its SPS Capstone™ business. This action was taken due to regulatory changes and uncertainty that have caused reduced demand and market deselection of telomer-based chemistries, making SPS economics unfavorable going forward. As a result, during the first quarter of 2025, the Company recorded charges of $27 million⁵. The Company remains on track to complete the exit of this business and end all manufacturing of SPS Capstone™ products by the end of the second quarter of 2025⁶, pending regulatory approval.

Other Non-Reportable Segment

The Performance Chemicals and Intermediates business in the Company’s Other Non-Reportable Segment had Net Sales and Adjusted EBITDA for the first quarter 2025 of $11 million and $1 million, respectively.

Corporate Expenses⁷

Corporate Expenses were a $57 million offset to Adjusted EBITDA in the first quarter 2025, a slight increase compared to the prior-year quarter. This was primarily due to higher legal costs in advance of upcoming trials⁸, partially offset by lower costs associated with the Audit Committee’s internal review and remediation of material weaknesses, which were completed in 2024⁹.

Liquidity and Capital Allocation

As of March 31, 2025, consolidated gross debt was $4.1 billion. Debt, net of $464 million in unrestricted cash and cash equivalents, was $3.7 billion, resulting in a net leverage ratio of approximately 5.0x on a trailing twelve-month Adjusted EBITDA basis. Total liquidity was $1.1 billion, comprised of $464 million in unrestricted cash and cash equivalents and $623 million of revolving credit facility capacity, net of outstanding letters of credit.

Operating cash usage for the first quarter of 2025 was $112 million, compared to $290 million in the prior-year quarter. The decrease in operating cash outflows in the first quarter of 2025 was primarily due to the unwinding of year end 2023 net working capital actions in the first quarter of 2024. Capital expenditures for the first quarter of 2025 amounted to $84 million, a decrease in spend compared to the prior-year quarter, driven by lower capital expenditures across each business. Free cash flows for the first quarter of 2025 reflected a use of $196 million compared with a use of $392 million in the prior year quarter. During the quarter, the Company paid $37 million in dividends to shareholders.

To align with Chemours’ Pathway to Thrive strategy, rooted in a balanced and disciplined approach to drive shareholder value, the Company announced an amendment and extension to its credit agreement to strengthen our liquidity profile and financial flexibility. The amended credit facility extends commitments to 2030 with a capacity of up to $1 billion¹⁰ until October 2026.

The Company is announcing a 65% reduction in its quarterly dividend to $0.0875 per share commencing with the Board of Directors’ second quarter dividend declaration yesterday¹¹, which better aligns our capital allocation with strategic priorities under Pathway to Thrive and our commitment to balance sheet flexibility. Since its inception, the Company has consistently maintained a long practice of returning capital to its shareholders, which will remain a strategic priority going forward inclusive of this revised dividend structure.

Second Quarter 2025 Outlook

In the second quarter, the Company anticipates consolidated Net Sales to increase in the low to mid-teens sequentially, with consolidated Adjusted EBITDA also expected to increase within a range of 40% to 45%. Corporate Expenses, as an offset to Adjusted EBITDA, are expected to decrease in the low single-digits compared with the first quarter. The Company also anticipates free cash flow in the second quarter to be slightly positive, paired with capital expenditures in the range of $50 million.

TSS anticipates an overall sequential Net Sales increase in the low 20% range, driven by double-digit sequential growth expected in both Opteon™ Refrigerants and Freon™ Refrigerants, reflecting traditional seasonality. TSS Adjusted EBITDA is expected to increase approximately 30% sequentially, primarily driven by strong volume increases and expected favorable pricing impacts.

TT expects a sequential Net Sales increase in the high single-digits, driven by a seasonal increase in volume primarily in our western markets. Adjusted EBITDA is also expected to increase in the low 40% range sequentially due to the anticipated seasonal volume increase and operating tailwinds following the cold weather downtime at our U.S. sites which we don’t anticipate to recur.

APM expects a sequential Net Sales increase in the low-teens, with volumes across the segment expected to increase driven by seasonality in customer demand. Adjusted EBITDA is anticipated to remain consistent sequentially.

Full Year 2025 Outlook

The Company expects to deliver Adjusted EBITDA of $825 million to $950 million in 2025. Anticipated capital expenditures are expected to range between $225 million to $275 million, and while anticipating free cash flow to be slightly positive in the second quarter, the Company projects free cash flows conversion to be in the range of 60-80% in the second half. This outlook assumes the existing tariff environment and known direct impacts to the business and no larger indirect impacts from tariffs on the macroeconomic environment or recessionary impacts.

Conference Call

As previously announced, Chemours will hold a conference call and webcast on May 7, 2025, at 8:00 AM Eastern Daylight Time. Access to the webcast and materials can be accessed by visiting the Events & Presentations page of Chemours’ investor website, investors.chemours.com. A webcast replay of the conference call will be available on Chemours’ investor website.

About The Chemours Company

The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers’ biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 6,000 employees and 28 manufacturing sites and serves approximately 2,500 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.

Non-GAAP Financial Measures

We prepare our financial statements in accordance with Generally Accepted Accounting Principles (GAAP). Within this press release, we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Free Cash Flows, Free Cash Flows Conversion, Total Debt Principal, Net and Net Leverage Ratio which are non-GAAP financial measures. The Company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Management uses Adjusted Net Income, Adjusted EPS and Adjusted EBITDA, which adjust for (i) certain non-cash items, (ii) certain items we believe are not indicative of ongoing operating performance or (iii) certain nonrecurring, unusual or infrequent items to evaluate the Company's performance in order to have comparable financial results to analyze changes in our underlying business from period to period. Additionally, Free Cash Flows, Free Cash Flows Conversion, Total Debt Principal, Net and Net Leverage Ratio are utilized as liquidity measures to assess the cash generation of our businesses and on-going liquidity position.

Accordingly, the Company believes the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company's operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. This analysis, as well as the other information in this press release, should be read in conjunction with the Company's financial statements and footnotes contained in the documents that the Company files with the U.S. Securities and Exchange Commission. The non-GAAP financial measures used by the Company in this press release may be different from the methods used by other companies. The Company does not provide a reconciliation of certain forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For more information on the non-GAAP financial measures, please refer to the attached schedules or the table, "Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited)" and materials posted to the Company's website at investors.chemours.com.

Forward-Looking Statements

This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, guidance on Company and segment performance for the second quarter of 2025, the full year 2025 and the Company’s refreshed corporate strategy. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as guidance relying on models based upon management assumptions regarding future events that are inherently uncertain. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties including the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, our ability to maintain an effective internal control over financial reporting and disclosure controls and procedures, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, changes in regulations in the US or other jurisdictions that could impose tariffs or additional costs on products we either sell or need to purchase, anticipated future operating and financial performance for our segments individually and our company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, efforts to resolve outstanding or potential litigation, including claims related to legacy PFAS liabilities, plans for dividends, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to develop and commercialize new products or technologies and obtain necessary regulatory approvals, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements also may involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions, changes in laws and regulations in the U.S. or other jurisdictions in which we operate, and global health events and weather events, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, and in our Annual Report on Form 10-K for the year ended December 31, 2024. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250506890353/en/